Slovakia – Medicinal products for the musculo-skeletal system – BUROSUMAB 2

The subject of the contract is the supply of the drug: burosumab 20mg injection solution and burosumab 30 mg injection solution with the active substance burosumab, known as Crysvita (hereinafter referred to as the "product"), for paediatric patients with X-linked form of hypophosphataemic rickets, provided that all of the following criteria are met: 1) with documented high serum concentration of FGF-23 2) with genetically confirmed mutation in PHEX gene 3) persistence of low hypophosphataemia despite long-term substitution with maximum tolerated doses of phosphate solution and active form of vitamin D 4) in the progression of bone deformities despite the administration of maximum tolerated doses of standard treatment (phosphates and vitamin D)